GO-203-2C

DB15008InvestigationalSmall molecule

GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

Formula / weight: C₈₉H₁₇₀N₅₂O₂₀S₂ · 2352.8 g/mol (avg)
Code names: GO-203-2C

Resolves to

Compound

UNII5YSY733NA3CAS1469735-88-3ChEMBLCHEMBL4297466

Structure

InChIKeyMDQMFOHHSFMREL-YIYMUJAPSA-NSMILES

[H][C@](CCCNC(N)=N)(N=C(C)O)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]1([H])CSSC[C@@]([H])(N=C(O)[C@@]([H])(CCC(O)=N)N=C1O)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCNC(N)=N)C(O)=N[C@]([H])(CCCCN)C(O)=N[C@]([H])(CC(O)=N)C(O)=O

Targets

P15941MUC1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with GO-203-2C, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account